NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT03845270 2023-12-19
R2D2
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT01679743 2019-11-15
GRN1005 for Brain Metastases From Breast or Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00016367 2018-10-26
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003881 2013-06-21
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00758134 2013-05-29
Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
Istituto Clinico Humanitas
Phase 2 Terminated
NCT00004883 2013-01-16
Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2
National Cancer Institute (NCI)
Phase 2 Completed